A landmark central liver resection
Wu Mengchao performed the world's first complete central liver resection, overcoming technical challenges in complex liver surgery at the time.
The Third Affiliated Hospital of Naval Medical UniversityEastern Hepatobiliary Surgery Hospital
A major birthplace of liver surgery in China, founded by a recipient of the nation's highest science award.
Founded under Academician Wu Mengchao's leadership, Eastern Hepatobiliary Surgery Hospital is rooted in Chinese innovations including the five-lobe, four-segment liver anatomy theory, intermittent hepatic inflow occlusion and central liver resection. Wu received the 2005 State Preeminent Science and Technology Award. The team's liver cancer surgery framework later earned a 2014 National Science and Technology Progress Second Prize, extending this heritage into recurrent liver cancer, intrahepatic cholangiocarcinoma and combined treatment research.
Shanghai, China
From pioneering liver surgery to building a liver cancer treatment framework.
Eastern Hepatobiliary's standing comes from pioneering contributions to liver anatomy, surgical bleeding control and complex resection. Wu Mengchao's research group grew into a hospital and institute, continually translating clinical questions into research on advanced liver cancer, cholangiocarcinoma and postoperative recurrence.
The hospital connects hepatobiliary surgical heritage, nationally recognized science and contemporary clinical trials within one specialist system.
National honors and original contributions
Foundational liver surgery work and award-winning projects
Founding discipline leader Wu MengchaoState Preeminent Science and Technology Award
2005 award, presented in 2006
Key technologies in liver cancer surgeryNational Science and Technology Progress Second Prize
2014 · Eastern Hepatobiliary was the first-ranked institution
Liver surgery theories and techniquesChinese innovation
Five-lobe, four-segment theory and intermittent hepatic inflow occlusion
The awards belong respectively to the named scientist and specified research team.
Establishing key theories and techniques in Chinese liver surgery
Wu Mengchao proposed the five-lobe, four-segment anatomical theory, developed intermittent hepatic inflow occlusion at normal temperature, and pioneered landmark procedures including central liver resection, laying foundations for anatomical localization and bleeding control.
National Science and Technology Progress Second Prize for a liver cancer surgery framework
The 2014 award-winning project addressed intermediate and advanced liver cancer, intrahepatic cholangiocarcinoma and postoperative recurrence. It proposed new surgical strategies, prognostic criteria and recurrence prevention and treatment approaches. Ministry of Science and Technology records state that related findings were adopted by seven international guidelines.
Randomized comparison of treatments for recurrence
A randomized trial of 240 patients with early recurrent liver cancer compared repeat resection with radiofrequency ablation and was published online in JAMA Oncology in 2019. It evaluated the approaches in a defined population, providing direct comparative evidence for retreatment decisions.
Establishment as an independent specialist hospital
The hepatobiliary clinical and research system founded under Wu Mengchao's leadership developed into the independently organized Eastern Hepatobiliary Surgery Hospital.
Wu Mengchao receives China's highest science award
His contributions to liver surgery theory, technical systems and professional training earned the 2005 State Preeminent Science and Technology Award, presented in 2006.
National award for a key liver cancer surgery framework
With Eastern Hepatobiliary as the first-ranked institution, the work received the 2014 National Science and Technology Progress Second Prize, presented in 2015.
Leading specialties,
built on medical achievements.
Explore Eastern Hepatobiliary Surgery Hospital's contributions in each field, from specialty standing to notable achievements, and the conditions this expertise supports.
A National Science and Technology Progress Second Prize-winning specialty team
2014 project: innovation and application of key technologies to improve surgical treatment of liver cancer
Beginning with liver anatomy and safe resection, hepatobiliary surgery gradually incorporated intrahepatic cholangiocarcinoma stratification, postoperative liver cancer recurrence and management of underlying liver disease into clinical research.
Pioneering liver anatomy and bleeding-control techniques
Foundations of the discipline · Chinese innovationThe five-lobe, four-segment theory and intermittent hepatic inflow occlusion addressed fundamental problems in localization and bleeding control during liver resection, becoming defining elements of Wu Mengchao's liver surgery framework.
Systematic advances in advanced liver cancer, cholangiocarcinoma and recurrence management
2014 · National Science and Technology Progress Second PrizeThe national award project connected surgical strategies, prognostic stratification in intrahepatic cholangiocarcinoma and recurrence prevention and treatment. Related research was adopted by seven international guidelines.
Directly comparing two approaches for recurrent liver cancer
Online in 2019 / Print in 2020 · JAMA OncologyA randomized trial of 240 patients compared repeat resection with percutaneous radiofrequency ablation. Overall survival did not differ significantly, informing trade-offs for patients with early recurrence who met the study criteria.
Clinical and research platforms for liver cancer
The hospital and research institute developed together. A liver cancer center was completed in 2017, with campuses in Yangpu and Jiading.
Coordinating tumor care and underlying liver disease
Zhou Weiping is a corresponding author of the 2023 consensus on antiviral treatment for hepatitis B-related hepatocellular carcinoma, reflecting continued attention to viral liver disease in liver cancer care.
What conditions can this expertise help address?
Clinical areas include initial surgery for hepatocellular carcinoma, retreatment of complex or recurrent liver cancer, and biliary tumors such as intrahepatic cholangiocarcinoma. Assessment considers lesion extent, remaining liver function and previous treatment to coordinate surgery, ablation and combined care.
Meet the specialists
through their achievements.
Discover the specialists' contributions and the conditions and treatments they focus on.
Showing 2 representative specialists
Shen Feng
Hepatobiliary surgery
Chief physician · Hepatobiliary surgery specialist
First-ranked contributor to a 2014 National Science and Technology Progress Second Prize
Ask about this doctorA first-ranked national science award contributor advancing liver cancer surgery and recurrence management
His surgical and clinical research addresses liver cancer, intrahepatic cholangiocarcinoma and postoperative recurrence, combining prognostic stratification, surgical selection and long-term treatment.
First-ranked contributor to a National Science and Technology Progress Second Prize
The 2014 award list names Shen Feng as first-ranked contributor and Eastern Hepatobiliary as first-ranked institution. The project covers liver cancer surgical strategies, cholangiocarcinoma prognostic stratification and recurrence prevention and treatment.
Corresponding author of a randomized recurrent liver cancer trial
He served as a co-corresponding author of the 240-patient trial comparing repeat resection with radiofrequency ablation, contributing to design and supervision. In 2020 he also received the Ho Leung Ho Lee Foundation Science and Technology Progress Award in medicine and pharmacy.
Conditions and treatment expertise
- Hepatocellular carcinoma and postoperative recurrence
- Surgery for primary liver cancer, selection between repeat resection and other local treatments for recurrence, and comprehensive assessment of recurrence risk.
- Intrahepatic cholangiocarcinoma
- Surgical treatment and prognostic stratification assessment informed by tumor extent, stage and liver function.
Zhou Weiping
Hepatobiliary surgery
Chief physician · Professor
Fourth-ranked contributor to a 2014 National Science and Technology Progress Second Prize
Ask about this doctorA surgeon connecting liver cancer surgery with hepatitis B management
He has long practiced primary liver cancer surgery, contributing to key technological research and antiviral consensus for hepatitis B-related liver cancer.
A principal contributor to a National Science and Technology Progress Second Prize
He was fourth-ranked contributor to the 2014 liver cancer surgery technology framework project, working with the team on intermediate and advanced liver cancer, cholangiocarcinoma and recurrence management.
Corresponding author of the 2023 antiviral treatment consensus
He helped develop the Chinese expert consensus on antiviral treatment for hepatitis B virus-related hepatocellular carcinoma, advancing coordination of cancer surgery and viral liver disease care.
Conditions and treatment expertise
- Primary liver cancer and complex liver tumors
- Specialist assessment for liver cancer resection, discussing surgery according to tumor location, extent and liver reserve.
- Comprehensive management of hepatitis B-related liver cancer
- Coordination of antiviral treatment during liver cancer care, and follow-up of postoperative recurrence risk and underlying liver disease.
These profiles describe professional expertise and notable experience. The doctor, campus and appointment time are confirmed when arranging care.
Want to learn about Eastern Hepatobiliary Surgery Hospital?
Contact us directly.
Tell eastmedgo about the specialty, doctor or care question that matters to you, through WhatsApp or email.
Initial service inquiries are free. Medical assessments and treatment recommendations are provided by the receiving hospital and doctors.
Related reading
Medical guides related to this hospital’s specialties.
Hepatobiliary surgery
HCC resection or ablation: why a Shanghai review starts with liver reserve
Compare the questions behind liver resection and ablation for localized HCC, including liver reserve, tumour position and a practical Shanghai assessment plan.
Read articleCan recurrent liver cancer be treated again? Reassessing options in Shanghai
After HCC recurrence, find out when repeat surgery or ablation remains possible, what other treatments may help, and how Shanghai teams can review the next step.
Read articleWhy bile duct cancer location changes a Shanghai surgical review
Understand how intrahepatic, perihilar and distal cholangiocarcinoma lead to different operations, drainage questions and preparation.
Read article